SynthesisMycopathologia2013
Chromoblastomycosis in Mainland China: a systematic review on clinical characteristics.
Synthesis in Mycopathologia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- The global burden of chromoblastomycosis.PLoS neglected tropical diseases · 2021Pooled it
- From molecular advances to limited clinical impact: The persistent gap in chromoblastomycosis.PLoS neglected tropical diseases · 2026Review
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China.Tropical medicine and health · 2025Review
- The role of melanin inFuture microbiology · 2025Article
- Analysis of the effect of ALA-PDT on macrophages in footpad model of mice infected withOpen medicine (Warsaw, Poland) · 2025Article
- Molecular epidemiology and clinical-laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil.Mycoses · 2022Article
- Chromoblastomycosis: A case series from Eastern China.PLoS neglected tropical diseases · 2022Article
- Chromoblastomycosis-Leprosy Co-Infection in Central West Brazil. Presentation of Three Cases and Literature Review.Mycopathologia · 2022Review
- Pathogenicity and Growth Conditions ModulateFrontiers in cellular and infection microbiology · 2022Article
- Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis.Journal of fungi (Basel, Switzerland) · 2020Review
- Chromoblastomycosis in an Endemic Area of Brazil: A Clinical-Epidemiological Analysis and a Worldwide Haplotype Network.Journal of fungi (Basel, Switzerland) · 2020Article
- Antimicrobial and immunomodulatory responses of photodynamic therapy in Galleria mellonella model.BMC microbiology · 2020Article
- Effect of Fonsecaea monophora on the Polarization of THP-1 Cells to Macrophages.Mycopathologia · 2020Article
- A screening of the MMV Pathogen Box® reveals new potential antifungal drugs against the etiologic agents of chromoblastomycosis.PloS one · 2020Article
- Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro.PLoS neglected tropical diseases · 2019Article
- Infectious dermatoses that can manifest as vesicles.Infection and drug resistance · 2019Article
- Indoor wet cells as a habitat for melanized fungi, opportunistic pathogens on humans and other vertebrates.Scientific reports · 2018Article
- High-resolution melting analysis assay for identification of Fonsecaea species.Journal of clinical laboratory analysis · 2018Article
- Chromoblastomycosis.Clinical microbiology reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromoblastomycosis is one of the most frequent chronic infections caused by melanized fungi. In order to evaluate the clinical characteristics of chromoblastomycosis in Mainland China, we performed an evidence-based review of published literature. PubMed and Chinese-language database of CNKI, VIP and Wanfang data during January 1990-August 2011 were searched. Epidemiology, clinical features, laboratory findings, therapy and prognosis were analyzed. Cladophialophora carrionii was the most common causative agent in the north of the Mainland China, and Fonsecaea monophora and F. pedrosoi were the most common agents in the southern part of the Mainland China. Infection commonly initiated after the etiologic agents gain entrance through puncture wounds and more common involved extremities of the males. Skin lesions were found in different sites, like the extremities, buttocks, trunk and face, and presented diversity morphology. There were about seven different clinical types found in Mainland China: plaque type, tumoral type, cicatricial type, verrucous type, pseudo-vacuole type, eczymatous type and mixed type of lesions. The success of treatment for chromoblastomycosis was related to the causative agent, the clinical form and severity of the lesions. Most of the patients could be treated successfully with the physical treatment, chemotherapy and/or combination therapy. The itraconazole, terbinafine or a combination of both were commonly medication for these mycosis patients. Physical methods were usually indicated to support chemotherapy with some severe forms and long-lasting cases. Photodynamic therapy has been extended from the oncological field to that of antimicrobial chemotherapy in these years. We applied it on some recalcitrant cases of chromoblastomycosis and found its good clinical response, and hopeful it could be a promising therapy in near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.